secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sight Sciences, Inc. (SGHT)
CIK:        0001531177
Form:       8-K
Filed at:   2025-03-05T23:59:59+00:00
Accession:  0000950170-25-033556
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sight Sciences reports Q4 revenue $19.1M (+2% YoY); guides FY2025 revenue down 6%-12%
--------------------------------------------------------------------------------

- Q4 total revenue $19.1M (+2% YoY); Surgical Glaucoma $18.8M (+9%), Dry Eye $0.3M (down from $1.6M).
- FY2024 net loss $51.5M ($1.03/shr) vs $55.5M ($1.14/shr) prior; cash used $17.8M (62% improvement YoY).
- FY2025 revenue guidance $70M-$75M (6%-12% decline) citing new Medicare LCDs restricting MIGS coverage with cataract.
- Adj. operating expenses FY2025 guided $105M-$107M (+4-6%); next-gen OMNI expected H1 2025.
- Gross margin Q4 87% vs 85% prior; cash and equivalents $120.4M at Dec 31, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1531177/000095017025033556/0000950170-25-033556-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1531177/000095017025033556/sght-20250305.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-033556

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer